James Goldstein, MD
Cardiovascular Disease · Royal Oak, MINPI 1407830847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Boston Scientific at 27.8% of the total. 2025 is the largest year on record at $985, 2.8 times the $352 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in MI, where the typical reported total is $2,775.
Across 94 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$573
- AstraZeneca$215
- Abbott$200
- E.r. Squibb & Sons, L.L.C.$173
- Merck$164
- Boehringer Ingelheim$161
- plus $572 from 15 others
Across 3 payments — averaging $187,329 each. An ownership or investment interest held by the physician or an immediate family member.
- Spectrawave, Inc$562K
What the payments were for
- Grants$271%
- Food & beverage$2,03199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 30 | $573 |
| AstraZeneca | 6 | $215 |
| Abbott | 4 | $200 |
| E.r. Squibb & Sons, L.L.C. | 4 | $173 |
| Merck | 9 | $164 |
| Boehringer Ingelheim | 8 | $161 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $100 |
| Spectrawave, Inc | 1 | $96 |
| Alnylam Pharmaceuticals Inc. | 4 | $66 |
| Amgen | 3 | $53 |
| Edwards Lifesciences | 2 | $40 |
| Novartis | 2 | $31 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| Pfizer | 1 | $29 |
| Cook Medical LLC | 2 | $27 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Abiomed | 1 | $20 |
| Novo Nordisk | 1 | $20 |
| Baxter Healthcare | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $15 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,058 in reported general payments places this provider in the 45th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $278,668 |
| Repatha SureclickEvolocumab | 360 | $229,412 |
| JardianceEmpagliflozin | 36 | $45,257 |
| EntrestoSacubitril/Valsartan | 35 | $39,554 |
| XareltoRivaroxaban | 29 | $34,808 |
| FarxigaDapagliflozin Propanediol | 20 | $18,045 |
| Praluent PenAlirocumab | 23 | $17,318 |
| Atorvastatin Calcium | 268 | $4,272 |
| Rosuvastatin Calcium | 157 | $3,659 |
| Ezetimibe | 146 | $2,760 |
| Metoprolol Succinate | 170 | $2,712 |
| Carvedilol | 189 | $2,440 |
| ClopidogrelClopidogrel Bisulfate | 107 | $2,309 |
| Bumetanide | 60 | $1,930 |
| Nitroglycerin | 46 | $1,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $278,668222 claims |
| Boehringer IngelheimJardiance | $161 | $45,25736 claims |
| NovartisEntresto | $31 | $39,55435 claims |
| AstraZenecaFarxiga | $215 | $18,04520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Royal Oak
- David HainesRoyal Oak$492K
- Douglas HorstmanshofRoyal Oak$407K
- Elvis CamiRoyal Oak$45K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.